聚焦世界卫生组织_米索前列醇和米非司酮护理点质量检测的目标产品概况。57 mifepristone in multiple countries, which can lead to inadequate efficacy (lower amount of API leading to reduced effectiveness) and safety concerns (such as impurities leading to increased risk of adverse reactions)1–3 58 .
聚焦世界卫生组织_米索前列醇和米非司酮护理点质量检测的目标产品概况。57 mifepristone in multiple countries, which can lead to inadequate efficacy (lower amount of API leading to reduced effectiveness) and safety concerns (such as impurities leading to increased risk of adverse reactions)1–3 58 .
聚焦世界卫生组织_米索前列醇和米非司酮护理点质量检测的目标产品概况。57 mifepristone in multiple countries, which can lead to inadequate efficacy (lower amount of API leading to reduced effectiveness) and safety concerns (such as impurities leading to increased risk of adverse reactions)1–3 58 .
覆盖 2026 年,全文共 44 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
适合战略规划等读者参考。
重点分析了护理、组织等议题。